Overall, HDAC2 inhibition disrupts PD-L1 nuclear translocation, potentially enhancing the therapeutic efficacy of immune checkpoint inhibitors and boosting antitumor immune responses for BC [19]. This evidence concerns the gene HDAC2 and breast cancer.